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Dementia in the older population is associated
with neocortex content of serum amyloid
P component
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Despite many reported associations, the direct cause of neurodegeneration responsible for cognitive loss in Alzheimer’s disease
and some other common dementias is not known. The normal human plasma protein, serum amyloid P component, a con-
stituent of all human fibrillar amyloid deposits and present on most neurofibrillary tangles, is cytotoxic for cerebral neurones
in vitro and in experimental animals in vivo. The neocortical content of serum amyloid P component was immunoassayed in
157 subjects aged 65 or more with known dementia status at death, in the large scale, population-representative, brain donor
cohort of the Cognitive Function and Ageing Study, which avoids the biases inherent in studies of predefined clinico-patho-
logical groups. The serum amyloid P component values were significantly higher in individuals with dementia, independent of
serum albumin content measured as a control for plasma in the cortex samples. The odds ratio for dementia at death in the
high serum amyloid P component tertile was 5.24 (95% confidence interval 1.79–15.29) and was independent of Braak tangle
stages and Thal amyloid-b phases of neuropathological severity. The strong and specific association of higher brain content
of serum amyloid P component with dementia, independent of neuropathology, is consistent with a pathogenetic role in
dementia.
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The cognitive loss that characterizes Alzheimer’s
disease and other common dementias is caused by
neurodegeneration, often associated with cerebral small
vessel disease, but the processes directly responsible for
dysfunction and death of cerebral neurones are poorly
understood. Serum amyloid P component (SAP), a
normal plasma protein which is a trace constituent of
CSF,1,2 has been reported to be neurotoxic for cerebral
neurones in vitro3–5 and in vivo.6 In these experimental
studies, SAP binds to the neuronal surface, is internal-
ized, traffics to the nucleus7 where it binds avidly to
chromatin8 and triggers apoptotic cell death.4,9 These
processes may also occur in vivo in humans, as SAP is
detectable by immunohistochemistry within some cere-
bral neurones even in normal adult brain (MB Pepys,
unpublished observations). Furthermore, SAP is a uni-
versal constituent of human amyloid deposits, including
the Ab amyloid deposits of Alzheimer’s disease and
cerebral amyloid angiopathy (CAA), and SAP is also
present on most neurofibrillary tangles (NFTs).10–12
This is due to the avid but reversible, specific, cal-
cium-dependent binding of SAP to all amyloid fibril
types and to the hyperphosphorylated tau of NFT.2
Bound SAP supports both formation13,14 and persist-
ence15 of Ab amyloid fibrils and may similarly stabil-
ize tangles.2 SAP may thus contribute to pathogenesis
of dementia by two distinct pathways, direct cerebral
neurotoxicity and enhancement of plaque and tangle
pathology, and is accordingly a valid therapeutic
target.2,16
Here, we report the first robustly scaled investigation
of the relationship between dementia and brain SAP con-
tent. SAP was assayed in samples of neocortex from the
brains of 157 participants in the Cognitive Function and
Ageing Study (CFAS), whose dementia status at death
was known and whose neuropathology was comprehen-
sively documented.
Materials and methods
The Cognitive Function and Ageing
Study
CFAS is a longitudinal study of cognitive impairment and
frailty in the UK population aged 65years and older (www.
cfas.ac.uk),17 which includes a population-representative
brain donation cohort. Dementia status of CFAS participants
was established using multiple information sources, including
Automated Geriatric Examination for Computer Assisted
Taxonomy (AGECAT), notification of dementia in death
certificates, a Retrospective Informant Interview (RINI;
www.cfas.ac.uk) with relatives and carers after death, and
the probability of having dementia before death from a
Bayesian analysis of all individuals modelling the prevalence
and incidence of dementia in CFAS. We could not assign
dementia status in 30 individuals in whom the study diagno-
sis was ‘no dementia’. These respondents were not included
in the analysis because their last interview was more than
6months before death, no RINI was available, and demen-
tia was not mentioned on the death certificate. Dementia
status was known for a total of 507 participants in CFAS,
of whom 257 were from the Cambridge, Oxford and
Newcastle Centres that have the neuropathological material
available. SAP was measured in the 157 subjects, comprising
60 men and 97 women, whose stored brains included fro-
zen frontal and/or temporal neocortex. As a control for the
presence of plasma as the source of the SAP detected, serum
albumin was also measured in 69 frontal cortex samples
from subjects with known dementia status. Dementia status
was known for the donors of 154 temporal and 128 frontal
neocortex samples. No hippocampus was available.
Tissue processing and serum
protein immunoassays
Samples of temporal (Brodmann Area 21, n¼ 154) and/
or frontal neocortex (Brodmann Area 8/9, n¼ 128) were
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expertly cryo-dissected to remove subcortical white matter
and arachnoid mater and a known mass of each was sus-
pended in 2ml chilled 10mM Tris buffered 140mM
NaCl at pH 8.0 containing 10mM ethylene diamine tet-
raacetic acid, 320mM sucrose and 0.5% v/v triton X-
100, to which 1% v/v Sigma P8340 protease inhibitors
(dimethyl sulphoxide solution of 104mM 4-(2-aminoe-
thyl)benzenesulfonyl fluoride hydrochloride; 80 lM apro-
tinin; 4mM bestatin; 1.4mM E-64; 2mM leupeptin;
1.5mM pepstatin A) was added immediately before use.
Inclusion of ethylene diamine tetraacetic acid is essential
for elution of SAP from its strictly calcium dependent
binding to amyloid fibrils and NFT. The tissue was
promptly homogenized (TissueLyser, Qiagen) at 50Hz
for 4min, then centrifuged at 10 600 g for 15min and the
supernatant removed for storage at 30C until assayed.
The SAP content was determined by a robustly reprodu-
cible immunoradiometric assay,18 calibrated with isolated
pure human SAP.19 There was complete recovery of SAP
added to control cortex samples before homogenization,
confirming that the tissue processing did not affect SAP
quantification. SAP content is expressed as ng/mg of neo-
cortex tissue. Serum albumin was assayed in homogenates
by enzyme-linked immunosorbent assay (Merck) cali-
brated precisely with standards of 99% pure human
serum albumin (Merck) quantified by A280 using the spe-
cific 1%, 1 cm extinction coefficient, 6.54, and expressed
as mg/mg neocortex tissue. All tissue processing and
immunoassays were conducted on coded samples, blind
to all subject information.
Statistical analysis
Only one cortical region was available in 32 subjects, 3
frontal and 29 temporal, while both regions were avail-
able in 125 subjects. For statistical analysis as the overall
neocortical SAP content, and designated as such, the
higher of the two values was adopted when both were
available and the single available value was used in the
other subjects. Based on associations in previous CFAS
analysis,20 modelling of effects on dementia risk was ap-
propriate for seven neuropathological variables. Braak
stage, Thal phase and CAA were included in the final
model, but the other variables (brain weight, age at
death, histological/imaging vascular disease, hippocampal
atrophy and Lewy bodies) were excluded due to dimin-
ished sample size and statistical power.
Differences in mean SAP by dementia status were
assessed using the Kruskal–Wallis test for continuous SAP
variables and the chi-square test for categorical analysis.
Pairwise comparison of means was used to assess SAP by
dementia status for individual Braak stages and Thal
phases, with P-values adjusted for multiple comparisons
by Tukey’s method.
Logistic regression models were used to analyse the re-
lationship between SAP content and dementia risk,
adjusted for the known neuropathology variables.
Neocortex content of SAP and albumin was analysed
by Spearman’s correlation coefficient with R2 representing
the explained variance.
Data availability
The data from this study are archived in the CFAS
Neuropathology Data Archive and are available using the
data application form.
Results
Dementia is associated with
neocortex SAP content
independently of plaque and tangle
burden
The mean and median neocortical SAP content values
were significantly higher in subjects who had dementia at
death than in those who did not, despite substantial over-
lap in the respective distributions (Table 1, Fig. 1A).
Since SAP is always present in intracerebral and cerebro-
vascular Ab amyloid deposits and on most NFT, the neo-
cortical SAP content might simply reflect the total burden
of amyloid and tangles. Indeed, there is a correlation be-
tween the SAP values and both the Braak NFT stages
and the Thal Ab phases. However, within each of these
neuropathological categories, the median SAP content
was higher in those with dementia (Fig. 1B and C).
Table 1 shows the risk of dementia at death according to
cortical SAP content, modelled by logistic regression ana-
lysis both with and without adjustment for the Braak
and Thal classifications and the CAA scores (Fig. 1D).
SAP content was independently related to dementia at
death, with odds ratio (OR) of 5.24 [95% confidence
interval (CI) 1.79–15.29] for the high SAP tertile.
Dementia was thus more closely associated with brain
SAP content than with classical neuropathology.
The SAP–dementia relationship is
independent of other
neuropathology variables
The prevalence of different neuropathology features
among the study population is shown in Table 2 accord-
ing to their dementia status. Sensitivity analyses including
each neuropathology variable univariately, and using a
multivariable model, showed that they did not influence
the relationship of SAP to dementia. In addition to the
model of SAP adjusted for Braak stages, Thal phases and
CAA, Table 3 shows the OR and 95% CI for SAP con-
tent and dementia risk adjusted for each of the neuro-
pathology variables.









































































Neocortex content of SAP and of
serum albumin are unrelated
The concentration of SAP in plasma is about 1000-fold
higher than in the CSF1,21 and the amount of SAP in the
homogenates could therefore be influenced by the pres-
ence of plasma in the neocortex samples. However, the
square of Spearman’s coefficient for the amounts of SAP
and albumin in the frontal cortex samples, R2, was 0.05,
showing that the albumin content explains less than 6%
of the variance in SAP content (Supplementary Fig. 1).
The SAP detected in the samples was thus unlikely to be
derived from the incidental presence of plasma and was
the content of the cortex itself. There was no significant
difference between the neocortical albumin content of
individuals with (n¼ 46) and without dementia at death
(n¼ 23); P¼ 0.91 for pairwise comparison of means.
Discussion
We show here, using the CFAS neuropathology cohort,
that dementia is related to brain SAP content.
Unsurprisingly, since SAP is bound to all Ab amyloid
deposits and to most NFTs, brain SAP content shows
some correlation with these neuropathological markers of
Alzheimer’s. However, we demonstrate that within given
stages of Alzheimer’s neuropathological change, neocor-
tical SAP content is higher in those with dementia.
Furthermore, the SAP–dementia relationship is independ-
ent of other neuropathological variables in a logistic
regression model, indicating a relationship of SAP to de-
mentia that is independent of classical neuropathological
lesions and is consistent with a pathogenic role.
Studies in CFAS, and other population-based neuro-
pathology studies, have demonstrated that classical neuro-
degenerative and vascular neuropathological lesions do
not account for all of dementia in the elderly population,
so that other factors may contribute to or modulate de-
mentia.17 The population-representative brain donation
cohort within this longitudinal study of cognitive impair-
ment and frailty in the population aged 65 years and
older (www.cfas.ac.uk),17 crucially enabled the present
separate assessment of the relationship of SAP content to
dementia and to neuropathology thus avoiding the biases
inherent in using clinico-pathological groups which have
been pre-defined by combining neuropathological meas-
ures with clinical dementia status. The only previous
study of brain SAP content and dementia comprised pre-
selected groups: 8 subjects with Alzheimer’s disease, 6
with Alzheimer’s disease neuropathology but not demen-
tia, 5 with mild cognitive impairment and 9 controls.22 It
suggested an association between cortical SAP content
and dementia that we here robustly confirm and extend.
Major strengths of the present study are its geographic-
ally and population-based data capture linked to a repre-
sentative donor programme, its longitudinal nature,
robust and standardized approaches to establishment of
clinical status before death, and careful post-mortem do-
nation process allowing storage for new data creation.
Although we have studied almost six times more subjects
than the only previous investigation of cortical SAP
Table 1 Mean neocortical SAP content (ng/mg tissue) by region and dementia status
No dementia Dementia Unadjusteda Adjusteda
n n Mean n Mean t P ORb 95% CIc ORb 95% CIc
Temporal SAP content
(n¼ 154)
154 65 0.30 89 0.55 4.76 <0.01 1.38 (1.18, 1.61) 1.34 (1.12, 1.61)
Frontal SAP content
(n¼ 128)
128 51 0.25 77 0.54 4.98 <0.01 1.50 (1.24, 1.81) 1.38 (1.13, 1.70)
Neocortical SAP
content (n¼ 157)
157 66 0.33 91 0.66 5.85 <0.01 1.45 (1.25, 1.70) 1.38 (1.15, 1.65)
Tertiles of neocortical
SAP content
Low 52 32 0.17 20 0.21 4.88 <0.01 Referenced Referenced
Middle 53 25 0.41 28 0.42 1.79 (0.82, 3.90) 1.10 (0.43, 2.83)
High 52 9 0.65 43 1.02 7.64 (3.08, 18.99) 5.24 (1.79, 15.29)
Braak stage 135 2.15 (1.26, 3.67)
0–II 50 32 0.30 18 0.58 2.64 <0.01 (0.03)
III–IV 56 21 0.38 35 0.65 2.67 <0.01 (0.03)
V–VI 29 2 0.23 27 0.78 2.09 0.04 (0.11)
Thal phase 138 1.11 (0.72, 1.71)
0–I 30 18 0.35 12 0.52 1.28 0.20 (0.61)
II–III 55 27 0.29 28 0.61 3.33 <0.01 (<0.01)
IV–V 53 11 0.38 42 0.77 3.32 <0.01 (<0.01)
a




CI, confidence interval.; P-values in parentheses show Tukey multiple comparisons correction.
d
The low tertile of the neocortical SAP content distribution was used as the reference category, corresponding to odds ratio of 1.









































































content, our sample size is still limited. In addition, the
hippocampus was not available although the key frontal
and temporal neocortex were included. Furthermore, the
only obvious confounder, the presence of plasma within
the neocortex samples, was eliminated by assay of serum
albumin in a substantial subset.
Circulating SAP is synthesized and catabolized only by
the liver and is not present in the normal adult human
brain transcriptome.23 Claims for local cerebral expres-
sion of SAP, based on mRNA detection, have not been
substantiated by direct measurements24; furthermore, de-
pletion of SAP from the blood in patients with
Alzheimer’s disease completely removed SAP from the
CSF.2 SAP thus only enters the brain from the blood and
the SAP concentration in the CSF is about one-thou-
sandth of the plasma concentration, a much lower ratio
than for other comparable plasma proteins. In addition
to exclusion by the blood–brain barrier, SAP may even
be actively transported across the barrier and out of the
brain.25 However, the age-associated decrease of blood–
brain barrier efficiency26 may attenuate protection of the
brain against SAP neurotoxicity. CFAS has reported that
the association of dementia with the neocortical neuritic
plaque burden decreases with age whilst the association
with cortical atrophy is unaffected.27 This is consistent
with the key role of neuronal and/or synaptic loss in de-
mentia and with a possible contribution of direct SAP
neurotoxicity, rather than other effects of plaques and
tangles. Furthermore, cerebral haemorrhage, traumatic
brain injury and severe or repeated non-penetrating head
injury, as in boxers and football players, are associated
with higher dementia risk. All these conditions comprom-
ise the blood–brain barrier and/or enable direct overex-
posure of cerebral neurones to circulating SAP.
Our present measurements of albumin content in the
neocortex samples show that the quantities of SAP that
are present, and that correlate with dementia status,
are not just the result of non-specific leakage through
the blood barrier. Despite the 100 000-fold greater
abundance of albumin than SAP in the CSF,1,2 the
amount of SAP relative to albumin was much greater in
all neocortex samples, consistent with specific retention
and persistence of SAP in the tissue.
SAP binds avidly and stably to both Ab amyloid fibrils
and NFT but the association of human dementia with
neocortex SAP content was independent of the abundance
of cerebral plaque and cerebrovascular amyloid as well
as NFTs. The association is therefore consistent with a
direct pathogenic role of SAP in neurodegeneration,
which can only be definitively established in vivo by a
specific therapeutic intervention. The safe and well toler-
ated drug, miridesap, hexanoyl bis(D-proline) previously
known as CPHPC, depletes circulating SAP by over 90%
for as long as the drug is administered16,28 and thereby
removes all SAP from the CSF2 and from intracerebral
and cerebrovascular amyloid deposits.29 The ongoing
DESPIAD (Depletion of serum amyloid P component in
Alzheimer’s disease), double-blind, placebo controlled, 1
year, phase 2b clinical trial of SAP depletion by miride-
sap in patients with Alzheimer’s disease, is monitoring
cortical atrophy, cerebral amyloid burden, cognition and
multiple other blood and CSF biomarkers including neu-
rofilament light chain, aiming to detect any significant
effects on disease progression (https://www.clinicaltrials
register.eu/ctr-search/trial/2016-003284-19/GB).
Figure 1 Descriptive statistics and logistic regression modelling of
the relationships between neocortical SAP content, dementia and
neuropathological staging. (A) Distribution of SAP values in
subjects with and without dementia, illustrated by violin plots
showing the higher median in those with dementia, the interquartile
range, the lower/upper adjacent values and outliers. (B)
Distribution of SAP values in subjects with and without dementia
with increasing severity of Braak stages. (C) Distribution of SAP
values in subjects with and without dementia with increasing
severity of Thal phases. (D) Risk of dementia according to SAP
values, adjusted for classical dementia neuropathology.










































































Supplementary material is available at Brain
Communications online.
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>89 13 (19.70) 36 (39.56) 2 (16.67)
CAA None/mild 30 (53.57) 24 (29.27) 5 (55.56)
Moderate 19 (33.93) 33 (40.24) 2 (22.22)
Severe 7 (15.50) 25 (30.49) 2 (22.22)
Histological/imaging vascular disease None 8 (14.81) 9 (12.00) 1 (16.67)
Infarct or haemorrhage 2 (3.70) 2 (2.67) 0
Lacunes/SVDb/DWMLc 35 (64.81) 38 (50.67) 2 (33.33)
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Severe 0 10 (13.89) 0
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Table 3 Logistic regression model of neocortical SAP
content and dementia risk
Neuropathologya ORb 95% CIc
Neocortical SAP 1.39 (1.02–1.88)
Thal phase 1.25 (0.54–2.91)
Braak stage 1.88 (0.76–4.63)
Lewy bodies 15.98 (0.80–318.66)
Brain weight (kg) 1.00 (0.99–1.00)
Age at death (years) 1.17 (1.03–1.33)
Cerebral amyloid angiopathy 0.73 (0.17–3.20)
Histological/imaging vascular disease 2.02 (0.70–5.78)
Hippocampal atrophy 1.42 (0.50–4.03)
aNeuropathology variables used to adjust OR for SAP and dementia risk.
bOdds ratio.
c95% confidence intervals.
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